Zobrazeno 1 - 10 of 213 pro vyhledávání: '"Daneshmanesh AH"'
1
Akademický článek
Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types.
Autor: Silva, Manuel A.1 (AUTHOR) manuel_agustin.silva_munoz@boehringer-ingelheim.com, Williams, Shuntae2 (AUTHOR), Hauert, Sylvie2 (AUTHOR), Ovadia, Benjamin3 (AUTHOR), Gupta, Indu3 (AUTHOR), Waldmeier, Lorenz4 (AUTHOR), Jaimes, Yarúa1 (AUTHOR), Al-Masri, Hytham2 (AUTHOR)
Publikováno v: PLoS ONE. 11/4/2024, Vol. 19 Issue 11, p1-13. 13p.
Zobrazit plný text záznamu
2
Akademický článek
Overview on Immunopathology of Chronic Lymphocytic Leukemia and Tumor-Associated Antigens with Therapeutic Applications.
Autor: Shabani, Mahdi1 msshabani@sbmu.ac.ir, Rostamzadeh, Davoud2, Mansouri, Mansoure1, Jeddi-Tehrani, Mahmood3
Publikováno v: Avicenna Journal of Medical Biotechnology. Oct-Dec2024, Vol. 16 Issue 4, p201-222. 22p.
Zobrazit plný text záznamu
3
Akademický článek
ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells.
Autor: Ghaderi A; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden., Daneshmanesh AH; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden., Moshfegh A; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden.; Kancera AB, Karolinska Institute Science Park, 171 48 Solna, Sweden., Kokhaei P; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden.; Department of Immunology, Semnan University of Medical Sciences, Semnan 35147-99442, Iran., Vågberg J; Kancera AB, Karolinska Institute Science Park, 171 48 Solna, Sweden., Schultz J; Kancera AB, Karolinska Institute Science Park, 171 48 Solna, Sweden., Olin T; Kancera AB, Karolinska Institute Science Park, 171 48 Solna, Sweden., Harrysson S; Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, 171 76 Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, 171 77 Stockholm, Sweden., Smedby KE; Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, 171 76 Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, 171 77 Stockholm, Sweden., Drakos E; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden.; Department of Pathology, Medical School, University of Crete, 71110 Heraklion Crete, Greece., Rassidakis GZ; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden., Österborg A; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, 171 77 Stockholm, Sweden., Hojjat-Farsangi M; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden., Mellstedt H; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden.
Publikováno v: Biomedicines [Biomedicines] 2020 Jun 23; Vol. 8 (6). Date of Electronic Publication: 2020 Jun 23.
Zobrazit plný text záznamu
4
Akademický článek
A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population.
Autor: Zweers TJ; Certara Inc, Department of Integrated Drug Development, Radnor, PA, USA., Lommerse J; Certara Inc, Department of Integrated Drug Development, Radnor, PA, USA., van Maanen E; Certara Inc, Department of Integrated Drug Development, Radnor, PA, USA., Chatterjee MS; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, NJ, USA. manash.chatterjee@merck.com.
Publikováno v: Clinical pharmacokinetics [Clin Pharmacokinet] 2024 Oct; Vol. 63 (10), pp. 1489-1499. Date of Electronic Publication: 2024 Oct 22.
Zobrazit plný text záznamu
5
Akademický článek
Genomic and transcriptomic landscape to decipher the genetic basis of hyperpigmentation in Lanping black-boned sheep (Ovis aries).
Autor: Chong, Yuqing1 (AUTHOR), Xiong, Heli1,2 (AUTHOR), Gao, Zhendong1 (AUTHOR), Lu, Ying1 (AUTHOR), Hong, Jieyun1 (AUTHOR), Wu, Jiao1 (AUTHOR), He, Xiaoming1 (AUTHOR), Xi, Dongmei1 (AUTHOR), Tu, Xiaolong3,4 (AUTHOR) tuxiaolong@mail.kiz.ac.cn, Deng, Weidong1 (AUTHOR) dengwd@ynau.edu.cn
Publikováno v: BMC Genomics. 9/9/2024, Vol. 25 Issue 1, p1-13. 13p.
Zobrazit plný text záznamu
6
Akademický článek
Novel humanized monoclonal antibodies against ROR1 for cancer therapy.
Autor: Wei, Rong1 (AUTHOR), Liao, Xun1 (AUTHOR), Li, Jiao1 (AUTHOR), Mu, Xiaoyu1 (AUTHOR), Ming, Yue1 (AUTHOR), Peng, Yong1,2 (AUTHOR) yongpeng@scu.edu.cn
Publikováno v: Molecular Cancer. 8/13/2024, Vol. 23 Issue 1, p1-17. 17p.
Zobrazit plný text záznamu
7
Akademický článek
First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.
Autor: Hojjat-Farsangi M; Department of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden., Daneshmanesh AH; Department of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden., Khan AS; Department of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden., Shetye J; Department of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden., Mozaffari F; Department of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden., Kharaziha P; Department of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden., Rathje LS; Department of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.; Kancera AB, Solna, Sweden., Kokhaei P; Department of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.; Cancer Research Center and Department of Immunology, Semnan University of Medical Sciences, Semnan, Iran., Hansson L; Department of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden., Vågberg J; Kancera AB, Solna, Sweden., Byström S; Kancera AB, Solna, Sweden., Olsson E; Kancera AB, Solna, Sweden., Löfberg C; Kancera AB, Solna, Sweden., Norström C; Kancera AB, Solna, Sweden., Schultz J; Kancera AB, Solna, Sweden., Norin M; Kancera AB, Solna, Sweden., Olin T; Kancera AB, Solna, Sweden., Österborg A; Department of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden., Mellstedt H; Department of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden. hakan.mellstedt@sll.se., Moshfegh A; Department of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.; Kancera AB, Solna, Sweden.
Publikováno v: Leukemia [Leukemia] 2018 Oct; Vol. 32 (10), pp. 2291-2295. Date of Electronic Publication: 2018 Mar 27.
Zobrazit plný text záznamu
8
Akademický článek
A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.
Autor: Daneshmanesh AH; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden., Hojjat-Farsangi M; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden., Ghaderi A; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden., Moshfegh A; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden., Hansson L; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden., Schultz J; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Vågberg J; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Byström S; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Olsson E; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Olin T; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Österborg A; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden., Mellstedt H; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden.
Publikováno v: PloS one [PLoS One] 2018 Jun 01; Vol. 13 (6), pp. e0198038. Date of Electronic Publication: 2018 Jun 01 (Print Publication: 2018).
Zobrazit plný text záznamu
9
Akademický článek
Incorporating network diffusion and peak location information for better single-cell ATAC-seq data analysis.
Autor: Yu, Jiating1,2,3 (AUTHOR), Leng, Jiacheng2,3,4 (AUTHOR), Hou, Zhichao2,3 (AUTHOR), Sun, Duanchen5 (AUTHOR) lywu@amss.ac.cn, Wu, Ling-Yun2,3 (AUTHOR) lywu@amss.ac.cn
Publikováno v: Briefings in Bioinformatics. Mar2024, Vol. 25 Issue 2, p1-13. 13p.
Zobrazit plný text záznamu
10
Akademický článek
Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia.
Autor: Khan AS; Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden., Hojjat-Farsangi M; Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden., Daneshmanesh AH; Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden., Hansson L; Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden., Kokhaei P; Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden.; Cancer Research Center and Department of Immunology, Semnan University of Medical Sciences, Semnan, Iran., Österborg A; Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden., Mellstedt H; Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden. hakan.mellstedt@karolinska.se.; Cancer Centre Karolinska, Department of Oncology, Karolinska University Hospital Solna, SE-171 76, Stockholm, Sweden. hakan.mellstedt@karolinska.se., Moshfegh A; Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden.
Publikováno v: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine [Tumour Biol] 2016 Sep; Vol. 37 (9), pp. 11947-11957. Date of Electronic Publication: 2016 Apr 16.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje